IL6 and cancer: It is a common serum marker for the assessment of inflammatory status.[12] Increased serum vascular growth factor and circulating interleukins in cancer patients contribute to elevated CRP and accelerated angiogenesis, which lead to drug resistance and low survival rates in patients with malignancies; thus, CRP has been shown to be a prognostic indicator for malignancies such as ovarian cancer, colorectal cancer, and oral cancer.[13,14] Tumor cells stimulate platelet activation, and IL-6 induces the differentiation of megakaryocytes into platelets.